Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer
Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA. Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Research And Treatment 2018, 169: 523-530. PMID: 29442264, PMCID: PMC5955803, DOI: 10.1007/s10549-018-4696-z.Peer-Reviewed Original ResearchAdultAgedBiomarkers, TumorBiopsyBreast NeoplasmsFemaleHumansImage Processing, Computer-AssistedMiddle AgedMultimodal ImagingNeoplasm GradingNeoplasm StagingPositron Emission Tomography Computed TomographyRadioisotopesRadiopharmaceuticalsReceptor, ErbB-2ROC CurveSensitivity and SpecificityTrastuzumabZirconium